A team of researchers reports the creation of an AI test that predicts the risk of breast cancer recurrence—one that does so more quickly and more inexpensively than current methods, which involve genomic testing. 

Korea University College of Medicine and Ulsan National Institute of Science and Technology (UNIST) have been selected for a new project under the Ministry of Health and Welfare’s 2026 Korea Medical Science & Technology (K-MediST) Program, supported by the Korea Health Industry Development Institute (KHIDI).

An engineered triphasic biomaterial scaffold successfully recreated the cranial suture stem cell niche lost in craniosynostosis, a condition that causes premature fusion of skull bones. Using a pore-size-guided “bone-suture-bone” design, the scaffold maintained skeletal stem cells while supporting surrounding bone formation. In mouse models, the construct prevented re-fusion, restored craniofacial growth, and improved skull morphology. The findings may advance regenerative therapies that directly address the underlying causes of pediatric craniofacial disorders.

A study led by the Sant Pau Research Institute and Hospital de Sant Pau characterizes for the first time in vivo how a brain signal sensitive to the tau protein is distributed across the different stages of the disease.

Molecular neuroimaging identifies tau-related alterations from the early stages of the disease and opens up new avenues for understanding and treating it.

The results reveal an organized anatomical pattern that depends on the stage of the disease, with particularly consistent alterations in the globus pallidus and additional changes in other subcortical and cortical regions.

The findings, published in the European Journal of Nuclear Medicine and Molecular Imaging, provide new insights into the biological processes that, beyond the causative genetic mutation, may influence disease onset, clinical expression, and progression, while suggesting new possibilities for the development of treatments and biomarkers.

New research offers fresh hope to patients with colorectal cancer, as advances in liquid biomarker technologies are poised to reshape detection, diagnosis and treatment of the disease.